KYMERA THERAPEUTICS Trademark

Trademark Overview

On Thursday, November 22, 2018, a trademark application was filed for KYMERA THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the KYMERA THERAPEUTICS trademark a serial number of 88985233. The federal status of this trademark filing is REGISTERED as of Tuesday, September 26, 2023. This trademark is owned by Kymera Therapeutics, Inc.. The KYMERA THERAPEUTICS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development of therapeutic drugs for the treatment of oncology, autoimmune, immune-oncology and other related diseases; Research and development of pharmaceuticals, and research and development of technology in the field of pharmaceuticals; Development of pharmaceutical preparations and medicines; Drug development and discovery; Medical research for development of therapeutic modalities for treatment of diseases; Clinical studies; Preclinical and clinical development of therapeutic products
kymera therapeutics

General Information

Serial Number88985233
Word MarkKYMERA THERAPEUTICS
Filing DateThursday, November 22, 2018
Status700 - REGISTERED
Status DateTuesday, September 26, 2023
Registration Number7176561
Registration DateTuesday, September 26, 2023
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 8, 2019

Trademark Statements

NOT AVAILABLE"THERAPEUTICS"
Goods and ServicesResearch and development of therapeutic drugs for the treatment of oncology, autoimmune, immune-oncology and other related diseases; Research and development of pharmaceuticals, and research and development of technology in the field of pharmaceuticals; Development of pharmaceutical preparations and medicines; Drug development and discovery; Medical research for development of therapeutic modalities for treatment of diseases; Clinical studies; Preclinical and clinical development of therapeutic products

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, December 12, 2018
Primary Code042
First Use Anywhere DateTuesday, October 31, 2017
First Use In Commerce DateTuesday, October 31, 2017

Trademark Owner History

Party NameKymera Therapeutics, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressWatertown, MA 02472
Party NameKymera Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWatertown, MA 02472
Party NameKymera Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139

Trademark Events

Event DateEvent Description
Monday, November 26, 2018NEW APPLICATION ENTERED
Wednesday, December 12, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, February 25, 2019ASSIGNED TO EXAMINER
Tuesday, February 26, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, February 26, 2019NON-FINAL ACTION E-MAILED
Tuesday, February 26, 2019NON-FINAL ACTION WRITTEN
Friday, August 23, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, August 23, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, August 24, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, September 3, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, September 5, 2019ASSIGNED TO LIE
Wednesday, September 18, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 8, 2019PUBLISHED FOR OPPOSITION
Tuesday, October 8, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, November 7, 2019OPPOSITION PAPERS RECEIVED AT TTAB
Thursday, November 14, 2019OPPOSITION INSTITUTED NO. 999999
Monday, November 2, 2020OPPOSITION DISMISSED NO. 999999
Thursday, December 3, 2020OPPOSITION TERMINATED NO. 999999
Thursday, December 3, 2020TTAB RELEASE CASE TO TRADEMARKS
Tuesday, January 12, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, July 12, 2021SOU TEAS EXTENSION RECEIVED
Monday, July 12, 2021SOU EXTENSION 1 FILED
Monday, July 12, 2021SOU EXTENSION 1 GRANTED
Wednesday, July 14, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 11, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, January 11, 2022SOU EXTENSION 2 FILED
Tuesday, January 11, 2022SOU EXTENSION 2 GRANTED
Thursday, January 13, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 12, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, July 12, 2022SOU EXTENSION 3 FILED
Tuesday, July 12, 2022SOU EXTENSION 3 GRANTED
Thursday, July 14, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 11, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, January 11, 2023SOU EXTENSION 4 FILED
Wednesday, January 11, 2023SOU EXTENSION 4 GRANTED
Friday, January 13, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 7, 2023DIVISIONAL REQUEST RECEIVED
Monday, July 10, 2023TEAS REQUEST TO DIVIDE RECEIVED
Monday, July 10, 2023USE AMENDMENT FILED
Monday, July 31, 2023TEAS STATEMENT OF USE RECEIVED
Monday, July 31, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, July 31, 2023STATEMENT OF USE PROCESSING COMPLETE
Monday, July 31, 2023DIVISIONAL PROCESSING COMPLETE
Tuesday, August 22, 2023ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Wednesday, August 23, 2023NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, September 26, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, September 26, 2023REGISTERED-PRINCIPAL REGISTER
Wednesday, June 26, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, June 26, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, June 26, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, June 26, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, June 26, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, June 26, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED

Related Keywords

therapeutics kymera development research therapeutic clinical diseases oncology treatment pharmaceuticals drug medical